Last reviewed · How we verify
Placebo for toripalimab — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for toripalimab (Placebo for toripalimab) — Shanghai Junshi Bioscience Co., Ltd.. Placebo is an inert substance with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for toripalimab TARGET | Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for toripalimab CI watch — RSS
- Placebo for toripalimab CI watch — Atom
- Placebo for toripalimab CI watch — JSON
- Placebo for toripalimab alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for toripalimab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-toripalimab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab